Evidence Regarding Pharmacogenetics in Pain Management and Cancer.

Published in: The oncologist (2023)

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

Keyphrases

pain management
chronic pain
clinical trial
genome wide
study protocol
phase iii
randomized controlled trial
dna repair
phase ii
gene expression
systematic review
oxidative stress
transcription factor
bone marrow
open label
double blind
placebo controlled
chemotherapy induced